

# Cancer Generics Market Analysis

<https://marketpublishers.com/r/C9E2F30E568EN.html>

Date: May 2012

Pages: 75

Price: US\$ 1,000.00 (Single User License)

ID: C9E2F30E568EN

## Abstracts

Across the globe, oncology market, one of the fastest growing segments of pharmaceutical industry, has been expanding on back of rising cancer incidences, and hefty investment by private players. According to our latest research report, the global cancer generics market is anticipated to grow at a compound annual rate of around 26% during 2011-2015 as many anti-cancer blockbuster drugs are on the verge of patent expiry, and governments are introducing biogenerics for controlling rapidly increasing healthcare costs.

The research report, "Cancer Generics Market Analysis", finds that the future holds tremendous potential as many drugs are under the development stage, and upon commercialization, they will boost the market in a significant manner. Our comprehensive report has effectively provided an insight into the global cancer generics market through proper analysis of drivers, restraints and key developments. The thorough study asserts that the players in the market have demonstrated their capabilities in terms of new launches and effective marketing.

On studying the market trends and drivers, we found that the US hospitals have reported a generic chemotherapy drug shortage in the recent times. The sharp rise in the number of ANDA and DMFs, especially in the oncology segment, by players from emerging countries is one of the successful instances that compliment the current status of the cancer generics market. Our in-depth study evaluates the current status and future potential of generic drugs in disease indications, such as lung cancer, breast cancer, colon cancer, stomach cancer and prostate cancer.

Our report covers all the key aspects of the global cancer generics market, including the competitive landscape that discusses profiles of leading players like Hospira and Accord Healthcare. A brief overview of oral and injectable generics has also been provided in the extensive study that aims at presenting an impartial picture of the market to clients.

## Contents

### **1. ANALYST VIEW**

### **2. RESEARCH METHODOLOGY**

### **3. CANCER INCIDENCES - CURRENT AND FUTURE PROJECTION**

### **4. CANCER MARKET OUTLOOK: CURRENT AND FUTURE**

#### 4.1 Cancer Generics: Market Size

### **5. MARKET DRIVERS AND TRENDS**

#### 5.1 US Facing Cancer Generics Shortage

#### 5.2 Oncology Therapeutics: Major Focus Area

#### 5.3 Strategic Activity and Alliances on the Rise

#### 5.4 Companies Thriving for New Generic Cancer Drugs

### **6. CANCER GENERIC DRUGS: MARKET SEGMENTATION BY DISEASE TYPES**

#### 6.1 Lung Cancer

##### 6.1.1 Current and Future Incidence

##### 6.1.2 Regional Analysis

##### 6.1.3 Commercialized Drugs: Branded and Generics

#### 6.2 Breast Cancer

##### 6.2.1 Current and Future Incidence

##### 6.2.2 Regional Analysis

##### 6.2.3 Commercialized Drugs: Branded and Generics

#### 6.3 Colorectal Cancer

##### 6.3.1 Current and Future Incidence

##### 6.3.2 Regional Analysis

##### 6.3.3 Commercialized Drugs: Branded and Generics

#### 6.4 Stomach Cancer

##### 6.4.1 Current and Future Incidence

##### 6.4.2 Regional Analysis

##### 6.4.3 Commercialized Drugs: Branded and Generics

#### 6.5 Prostate Cancer

##### 6.5.1 Current and Future Incidence

6.5.2 Regional Analysis

6.5.3 Commercialized Drugs: Branded and Generics

## **7. CANCER GENERIC DRUGS: MARKET SEGMENTATION BY ORAL AND INJECTABLES**

### 7.1 Oral Generic Drugs

7.1.1 Arimidex (Anastrozole)

7.1.2 Casodex (Bicalutamide)

7.1.3 Aromasin (Exemestane)

7.1.4 Femara (Letrozole)

7.1.5 Megace (Megestrol Acetate)

7.1.6 Purinethol (Mercaptopurine)

7.1.7 Tarceva (Erlotinib)

7.1.8 Nolvadex (Tamoxifen Citrate)

7.1.9 Eulexin (Flutamide)

7.1.10 Hydrea (Hydroxyurea)

### 7.2 Generic Injectables

7.2.1 Camptosar (Irinotecan Hydrochloride)

7.2.2 Velcade (Bortezomib)

7.2.3 Taxotere (Docetaxel)

7.2.4 Gemzar (Gemcitabine Hydrochloride)

## **8. KEY PLAYERS**

8.1 Accord Healthcare

8.2 Hospira

8.3 Mylan

8.4 Sun Pharmaceuticals

8.5 Teva

## List Of Figures

### LIST OF FIGURES:

- Figure 3-1: Global - Number of New Cancer Cases (Million), 2009 & 2020
- Figure 4-1: Global - Cancer Drugs Market (Billion US\$), 2011-2015
- Figure 4-2: Global - Cancer Market by Type of Drug (%), 2011
- Figure 4-3: Global - Cancer Generics Market (Billion US\$), 2011 & 2015
- Figure 5-1: US - Share of Drug Type in Drugs Shortages
- Figure 6-1: Global - Number of New Lung Cancer Cases (Million), 2009 & 2020
- Figure 6-2: Global - New Lung Cancer Cases by Region (%), 2009
- Figure 6-3: Global - Forecast for New Lung Cancer Cases by Region (%), 2020
- Figure 6-4: Global - Number of New Breast Cancer Cases (Million), 2009 & 2020
- Figure 6-5: Global - New Breast Cancer Cases by Region (%), 2009
- Figure 6-6: Global - Forecast for New Breast Cancer Cases by Region (%), 2020
- Figure 6-7: Global - Number of New Colorectal Cancer Cases (Million), 2009 & 2020
- Figure 6-8: Global - New Colorectal Cancer Cases by Region (%), 2009
- Figure 6-9: Global - Forecast for New Colorectal Cancer Cases by Region (%), 2020
- Figure 6-10: Global - Number of New Stomach Cancer Cases (Million), 2009 & 2020
- Figure 6-11: Global - New Stomach Cancer Cases by Region (%), 2009
- Figure 6-12: Global - Forecast for New Stomach Cancer Cases by Region (%), 2020
- Figure 6-13: Global - Number of New Prostate Cancer Cases (Million), 2009 & 2020
- Figure 6-14: Global - New Prostate Cancer Cases by Region (%), 2009
- Figure 6-15: Global - Forecast for New Prostate Cancer Cases by Region (%), 2020

## List Of Tables

### LIST OF TABLES:

Table 3-1: Global - New Cases of Top Five Cancer's by Geography (Number), 2009

Table 3-2: Global - Forecast for New Cases of Top Five Cancer's by Geography (Number), 2020

Table 5-1: Oncology Drug Master Filings by Market Players

Table 6-1: Global - Key Lung Cancer Drugs and Patent Expiry Status

Table 6-2: Global - Key Breast Cancer Drugs and Patent Expiry Status

Table 6-3: Global - Key Colorectal Cancer Drugs and Patent Expiry Status

Table 6-4: Global - Key Stomach Cancer Drugs and Patent Expiry Status

Table 6-5: Global - Key Prostate Cancer Drugs and Patent Expiry Status

Table 7-1: List of Companies Dealing in Generic Arimidex (Anastrozole)

Table 7-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)

Table 7-3: List of Companies Dealing in Generic Casodex (Bicalutamide)

Table 7-4: Cost Comparison of Generics and Branded Casodex (Bicalutamide)

Table 7-5: Cost Comparison of Generics and Branded Aromasin (Exemestane)

Table 7-6: List of Companies Dealing in Generic Femara (Letrozole)

Table 7-7: Cost Comparison of Generics and Branded Femara (Letrozole)

Table 7-8: List of Companies Dealing in Generic Megace (Megestrol Acetate)

Table 7-9: Cost Comparison of Generics and Branded Megace (Megestrol Acetate)

Table 7-10: List of Companies Dealing in Generic Purinethol (Mercaptopurine)

Table 7-11 Cost Comparison of Generics and Branded Purinethol (Mercaptopurine)

Table 7-12 Cost Comparison of Generics and Branded Tarceva (Erlotinib)

Table 7-13: List of Companies Dealing in Generic Nolvadex (Tamoxifen Citrate)

Table 7-14 Cost Comparison of Generics and Branded Nolvadex (Tamoxifen Citrate)

Table 7-15: List of Companies Dealing in Generic Eulexin (Flutamide)

Table 7-16 Cost Comparison of Generics and Branded Eulexin (Flutamide)

Table 7-17: List of Companies Dealing in Generic Hydrea (Hydroxyurea)

Table 7-18 Cost Comparison of Generics and Branded Hydrea (Hydroxyurea)

Table 7-19: List of Companies Dealing in Generic Camptosar (Irinotecan Hydrochloride)

Table 7-20: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)

Table 7-21: Cost Comparison of Generics and Branded Velcade (bortezomib)

Table 7-22: List of Companies Dealing in Generic Taxotere (Docetaxel)

Table 7-23 Cost Comparison of Generics and Branded Taxotere (Docetaxel)

Table 7-24: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)

Table 7-25 Cost Comparison of Generics and Branded Gemzar (Gemcitabine

Hydrochloride)

Table 8-1: Accord Healthcare - Key Cancer Generic Drugs

Table 8-2: Hospira - Key Cancer Generic Drugs

Table 8-3: Mylan - Key Cancer Generic Drugs

Table 8-4: Sun Pharmaceuticals - Key Cancer Generic Drugs

Table 8-5: Teva Pharmaceuticals - Key Cancer Generic Drugs

## I would like to order

Product name: Cancer Generics Market Analysis

Product link: <https://marketpublishers.com/r/C9E2F30E568EN.html>

Price: US\$ 1,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9E2F30E568EN.html>